PH
Insider
Patrick J Heron
DirectorPatrick J Heron (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in MBX. Across 2 priced purchase filings, the average 21-session return was +4.9% from execution and +6.1% from disclosure (delay-adjusted; derived). The largest single filing was $12.0M of MBX (666,666 sh × $18.00, as filed), executed Sep 26 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+4.9%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+6.1%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$9.0M
shares × price, as filed
Last traded
Jan 23
Filed Jan 27
Median ADV $83.1M across their filed names
Open performance→Volume by month
Buys $21.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Not on file
1 filing
Sector per market data · by filing · past 12 months
Most traded names
MBX
MBX
MBX · 1 buy · 0 sells
1 filing
MIRMRecent filings
MIRMPURCHASE
Mirum Pharmaceuticals, Inc.
View filing →
$9.0M131,425 sh × $68.48
Exec Jan 23
Filed Jan 27 · 4:14 PM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $12.0M
666,666 sh × $18.00
Exec Sep 26 2025
Filed Sep 30 2025 · 4:59 PM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $10.0M
625,000 sh × $16.00
Exec Sep 16 2024
Filed Sep 17 2024 · 5:30 PM ET